Neuropathic pain in a sample of Egyptian patients with rheumatoid arthritis

Abstract

Background

Rheumatoid arthritis (RA) is an autoimmune disease characterized by polyarthritis that may cause irreversible joint disability. Pain is the most important symptom in RA patients that requires more attention and careful evaluation. Despite the improvement in medications used to control inflammation in RA patients, a relevant number of them still experience neuropathic pain even with disease remission. This study was conducted to estimate the frequency of neuropathic pain (NP) in RA patients and to assess its relationship with disease activity, functional status, and overweight.

Results

NP was detected in 12.5% (14 patients) of RA patients. Highly significant differences were found between RA patients with NP and those without NP as regards disease duration, visual analog scale (VAS) of pain, disease activity score 28 (DAS28-ESR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), body mass index (BMI), health assessment questionnaire (HAQ) score, and Douleur Neuropathique in 4 (DN4) questionnaire for NP assessment (p < 0.001). The correlation between the DN4 questionnaire and the parameters of disease activity in RA patients with NP was not significant. By univariate analysis, the possible risk factors for NP in RA patients were disease duration, VAS, DAS28-ESR, HAQ, and BMI; however, by multivariate analysis, no possible risk factors for NP in RA patients were detected.

Conclusion

Although pain in patients with RA was classified as nociceptive in nature, a relevant proportion of patients might also have NP. NP in RA patients was related to functional disability, high disease activity, and overweight.

Background

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by persistent, progressive synovitis, and structural damage that can result in progressive disability and loss of function [1]. Despite the significant improvement in RA management, persistent pain still presents in a relevant number of RA patients. Careful pain evaluation in RA patients will result in more advanced control of pain and better disease outcome [2].

Pain in patients with RA was described as nociceptive pain (inflammatory) and neuropathic pain. The nociceptors stimulated by chronic inflammation will result in nociceptive pain [3]. The International Association for the Study of Pain (IASP) defined the neuropathic pain (NP) as “pain caused by a primary lesion or dysfunction in the nervous system” [4]. Both hyperalgesia and allodynia are pathognomonic of NP [5].

NP and non-NP require different treatment modalities, so, for optimal treatment of NP, it should be properly evaluated and correctly diagnosed [6]. Patients describe NP as burning, tingling, pins and needles, electric shock feeling, and sensitivity to heat, cold, touch, or pressure [7]. Because of the overlap that can occur between NP and nociceptive pain in the pathophysiological mechanisms, several instruments have been developed for the assessment of pain [8].

According to IASP, careful history taking, proper clinical neurological examination, and sensory testing are recommended for NP diagnosis. To differentiate NP from non-NP, several screening tools were recommended by IASP [9].

One of the screening tools used for NP assessment is the Douleur Neuropathique in 4 (DN4) score which was developed by the French neuropathic pain group. The Pain DETECT questionnaire (PD-Q) is another screening tool developed for the assessment of NP [10].

The present study was carried out to estimate the frequency of NP in RA patients and to assess its relationship with disease activity, functional disability, and overweight.

Methods

This study was cross-sectional and performed on RA patients who attended the outpatient clinic of the Department of Rheumatology and Rehabilitation of our University Hospital in the period between December 2018 and May 2019. One hundred and twelve patients (9 males and 103 females) fulfilling the American College of Rheumatology/European league against rheumatism (ACR/EULAR) criteria for a diagnosis of RA [11] were randomly selected. RA patients with neurological diseases such as cerebrovascular disorders, multiple sclerosis, and peripheral neuropathy; those with fibromyalgia; and those with endocrine diseases such as diabetes mellitus and thyroid disorders were excluded from the study.

Patients were subjected to full history taking and thorough clinical examination. The erythrocyte sedimentation rate (ESR) (mm/h), C-reactive protein (CRP) (mg/l), rheumatoid factor (RF) (U/ml), and anti-cyclic citrullinated peptide (anti-CCP) (U/ml) were assessed. The disease activity score 28 ESR (DAS28-ESR) [12], the visual analog scale (VAS) of pain [13], and the body mass index (BMI) were measured. The functional status was evaluated by the health assessment questionnaire (HAQ) [14].

In the present study, a combination of methotrexate (15 mg/week) and leflunomide (20 mg/day) were used for the treatment of RA patients. Due to the high cost of biologics, RA patients used this combination for good control of disease activity.

The NP was assessed by the DN4 score. This score is characterized by the easy translation to the Arabic language, simplicity in usage, and easy scoring. It included 10 items, seven of them included self-reported pain sensations (itching, tingling, numbness, pins and needles, painful cold, electric shock, and burning), while the remaining 3 items described the clinical findings (hypoesthesia to prick, hypoesthesia to touch, and brushing). Each item can be answered as “Yes” and takes 1 point or “No” and takes 0 points. The total score ranges from 0 to 10, and the score of 4 or more (≥ 4) is considered positive for NP. The sensitivity of this score is 83%, and the specificity is 90% for the diagnosis of neuropathic pain. The diagnostic accuracy of the DN4 score is higher than other questionnaires used for the determination of neuropathic pain because of the presence of physical examination in this score [10].

Statistical analysis: Data was analyzed using IBM-SPSS statistics version 24 (May 2016, IBM Corporation, Chicago, USA) Qualitative data were expressed as numbers and percentages while quantitative data were expressed as means and SD. Pearson’s chi-squared test was used to compare percentages in qualitative data. Student’s t test was used to compare the means between groups for quantitative data, and Mann Whitney’s test was used instead of a t test for non-parametric data. Pearson’s correlation coefficient test was used to estimate correlations between different variables for parametric data, and Spearman’s correlation test was used instead of non-parametric data. P-value was considered significant if ≤0.05 and highly significant if ≤0.001.

Results

A total of 112 patients with RA (9 males, 103 females; mean age 44.86 ± 10.1 years) were included in the study. The characteristics of RA patients with NP and those without NP are presented in Table 1. Highly significant differences were found between the two groups as regards disease duration, VAS, DAS28-ESR, ESR, CRP, BMI, HAQ, and DN4 (p < 0.001) (Table 1). The correlation between the DN4 questionnaire and parameters of disease activity in the group of RA patients with NP was not significant (Table 2). The univariate binary regression analysis showed that disease duration, VAS, total joint counts (TJCs), swollen joint counts (SJCs), DAS28-ESR, ESR, CRP, BMI, and HAQ are possible risk factors for NP in RA patients (Table 3); however, no possible risk factors for NP in RA patients were detected by the multivariate analysis (Table 4).

Table 1 Comparison between RA patients with neuropathic pain and those without neuropathic pain

Table 2 Comparison between Douleur Neuropathique in 4 (DN4) questionnaire and other variables among RA patients with neuropathic pain (n = 14)

Table 3 Univariate binary logistic regression analysis of the possible risk factors for neuropathic pain among RA patients

Table 4 Multivariate binary logistic regression analysis of the possible risk factors for neuropathic pain among RA patients

Discussion

RA is a common autoimmune arthritis characterized by synovial changes, cartilage and bone destruction, joint swelling, and pain with associated systemic inflammation. The prognosis and control of RA have greatly improved especially when biologic disease-modifying anti-rheumatic drugs (DMARDs) were introduced for its management. However, some RA patients still suffer from severe pain [15].

Pain is categorized into nociceptive pain, NP, and mixed pain. RA, osteoarthritis, and trauma are categorized as nociceptive pain. Diabetic neuropathy, sciatic pain, and post-herpetic neuralgia are categorized as NP. Post-operative pain, the pain of lumbar disc hernia, and pain of spinal canal stenosis are categorized as mixed pain [16]. The concept of mixed pain may also be applied to RA, because different pain mechanisms operate in this type of pain. In RA patients, because of the inadequate response of NP to the traditional anti-inflammatory medications, and the association between NP and poor quality of life, it is important to address the presence of NP symptoms in RA [17].

In our study, based on the DN4 scores, NP was detected in 12.5% (14 patients) of RA patients. According to DN4 scores, Perrot et al. [18] detected NP in 36% of patients with RA while Cengiz et al. [19] detected NP in 45.3% of RA patients. This may be explained by the racial differences and the different sample sizes in the studied populations. By using the PD-Q, NP was detected in 33% [20], in 17% [16], and in 11% [17] of RA patients. These results showed that, despite advancement in RA management, pain suppression in some patients remains inadequate, even with good control of inflammation. Therefore, inflammation is not the only parameter that predisposes to pain in RA; other parameters like NP can also have a role. Therefore, considering the NP component is essential in the optimal care of RA patients [19]. The first-line drugs for the management of NP were tricyclic antidepressant, pregabalin, and duloxetine, while the second line drug was tramadol. However, pregabalin is the only drug approved for treating NP in Japan [17]. Because the main adverse effects of pregabalin are weight gain and edema, attention should be paid to RA patients with NP when treating them with pregabalin.

In the present study, significantly higher levels of disease duration, VAS, DAS28-ESR, ESR, and CRP were reported in RA patients with NP than those without NP (p < 0.001). The univariate analysis detected these parameters as possible risk factors for neuropathic pain. However, no possible risk factors for NP were detected by the multivariate analysis. These results were consistent with those of Ito et al. [17] who found significantly higher levels of disease activity parameters in RA patients with NP than those without NP. The longer disease duration will give a chance to the neuropathic pain to become apparent. On the contrary, our results were inconsistent with those of Koop et al. [16]. According to these findings, more effective treatment strategies should be applied to RA patients especially those with NP.

In our study, patients with RA and NP showed significantly higher BMI values than those without NP. Similar results were found in other studies [17, 20]. However, no association between NP and BMI was detected in the multivariate analysis which was inconsistent with that of Ito et al. [17] who found that BMI > 22 was associated with NP in the multivariate analysis. Pain and obesity have a complex relationship, and the association between NP and obesity is still unclear [17]. It has been suggested that obesity may be related to pain [21], and in contrast, chronic pain may lead to a sedentary lifestyle, resulting in obesity [17].

In the current study, patients with RA and NP reported higher HAQ scores compared to those without neuropathic pain which were in line with those of Koop et al. [16]. No association between HAQ scores and NP was detected in the multivariate analysis. This can be explained by the fact that HAQ scores are subjective measures and therefore may not necessarily detect the true functional disability [16].

In the present study, the correlation between the DN4 questionnaire and disease activity parameters in RA patients was not significant. Our results were consistent with those of Koop et al. [16] but inconsistent with those of Perrot et al. [18]. This can be explained by the low sample size, racial difference, different disease duration and severity, and gender difference. Therefore, future larger studies are needed to clarify these results.

Limitations

First, NP diagnosis was only made by the DN4 questionnaire. Confirmation of the results can be done by using electrodiagnostic studies, including nerve conduction studies and electromyography. Second, for better interpretation of the present findings, another questionnaire like the PD-Q can be used in addition to the DN4 questionnaire in future studies. Third, psychological assessment for depression and anxiety that may be related to NP was not done. Fourth, it can be better to exclude RA patients treated with leflunomide because of leflunomide-induced neuropathy which may interfere with the interpretation of the present results. Finally, the low percentage of RA patients with NP and the predominance of females in the current study may prevent the generalization of the results. So, for an accurate understanding of NP in RA, future larger studies are needed to provide us with more professional approaches to pain management.

Conclusion

Although pain in RA patients is mainly classified as nociceptive, a relevant number of RA patients might also have NP. NP in RA patients is related to high disease activity, functional disability, and overweight.